Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Invested Capital for the quarter ending March 31, 2024: USD 440.86 M

Cogent Biosciences Inc Invested Capital is USD 440.86 M for the quarter ending March 31, 2024, a 81.40% change year over year. Invested capital represents the total amount of capital invested in a company's operations, including both equity and debt. It is calculated by subtracting the sum of current liabilities (excluding short-term debt) from the total assets of a company. Invested capital reflects the long-term financial resources employed in the company's operations. It is an important measure to evaluate a company's capital structure and assess the amount of capital invested in its productive assets.

Cogent Biosciences Inc Invested Capital for the quarter ending March 31, 2023 was USD 243.03 M, a 26.98% change year over year.
Cogent Biosciences Inc Invested Capital for the quarter ending March 31, 2022 was USD 191.38 M, a -17.32% change year over year.
Cogent Biosciences Inc Invested Capital for the quarter ending March 31, 2021 was USD 231.49 M, a 638.46% change year over year.
Cogent Biosciences Inc Invested Capital for the quarter ending March 31, 2020 was USD 31.35 M, a -44.46% change year over year.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends